CN1289098C - 溶瘤病毒 - Google Patents

溶瘤病毒 Download PDF

Info

Publication number
CN1289098C
CN1289098C CNB008158983A CN00815898A CN1289098C CN 1289098 C CN1289098 C CN 1289098C CN B008158983 A CNB008158983 A CN B008158983A CN 00815898 A CN00815898 A CN 00815898A CN 1289098 C CN1289098 C CN 1289098C
Authority
CN
China
Prior art keywords
vsv
virus
cells
sequence
pkr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB008158983A
Other languages
English (en)
Chinese (zh)
Other versions
CN1496268A (zh
Inventor
J·C·贝尔
N·索宁贝格
D·F·斯托德尔
E·G·布朗
H·L·阿特金斯
R·M·马里乌斯
B·D·利克蒂
S·B·诺勒斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
VIRUSTA BIOLOGICAL Inc
Original Assignee
VIRUSTA BIOLOGICAL Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by VIRUSTA BIOLOGICAL Inc filed Critical VIRUSTA BIOLOGICAL Inc
Publication of CN1496268A publication Critical patent/CN1496268A/zh
Application granted granted Critical
Publication of CN1289098C publication Critical patent/CN1289098C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/766—Rhabdovirus, e.g. vesicular stomatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0331—Animal model for proliferative diseases
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
    • C12N2760/20221—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
    • C12N2760/20222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
    • C12N2760/20232—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
    • C12N2760/20251—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
    • C12N2760/20261—Methods of inactivation or attenuation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
CNB008158983A 1999-09-17 2000-09-18 溶瘤病毒 Expired - Fee Related CN1289098C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39787399A 1999-09-17 1999-09-17
US09/397,873 1999-09-17

Publications (2)

Publication Number Publication Date
CN1496268A CN1496268A (zh) 2004-05-12
CN1289098C true CN1289098C (zh) 2006-12-13

Family

ID=23573018

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB008158983A Expired - Fee Related CN1289098C (zh) 1999-09-17 2000-09-18 溶瘤病毒

Country Status (13)

Country Link
EP (2) EP1716858B9 (enExample)
JP (1) JP5060694B2 (enExample)
CN (1) CN1289098C (enExample)
AT (2) ATE319460T1 (enExample)
AU (1) AU782402B2 (enExample)
CA (1) CA2386920C (enExample)
DE (2) DE60041210D1 (enExample)
ES (2) ES2260057T3 (enExample)
HK (1) HK1044708B (enExample)
IL (2) IL148621A0 (enExample)
MX (1) MXPA02002772A (enExample)
NZ (4) NZ534306A (enExample)
WO (1) WO2001019380A2 (enExample)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPQ425699A0 (en) 1999-11-25 1999-12-23 University Of Newcastle Research Associates Limited, The A method of treating a malignancy in a subject and a pharmaceutical composition for use in same
US7306902B2 (en) * 2002-06-28 2007-12-11 Oncolyties Biotech Inc. Oncolytic viruses as phenotyping agents for neoplasms
US8491884B2 (en) 2000-05-03 2013-07-23 Oncolytics Biotech Inc. Virus clearance of neoplastic cells from mixed cellular compositions
EP1297121B1 (en) 2000-06-26 2005-05-04 Wellstat Biologics Corporation Purging of cells using viruses
ATE500808T1 (de) 2001-05-11 2011-03-15 Wellstat Biologics Corp Onkolytische virustherapie
AU2008201293B2 (en) * 2001-07-11 2011-08-18 University Of Miami Recombinant VSV for the treatment of tumor cells
WO2003005964A2 (en) * 2001-07-11 2003-01-23 University Of Miami Recombinant vsv for the treatment of tumor cells
JP2004099584A (ja) 2002-05-02 2004-04-02 Keio Gijuku Ｈｓｖを用いた抗腫瘍剤
AU2002953436A0 (en) 2002-12-18 2003-01-09 The University Of Newcastle Research Associates Limited A method of treating a malignancy in a subject via direct picornaviral-mediated oncolysis
US7731974B2 (en) 2003-03-27 2010-06-08 Ottawa Hospital Research Institute Mutant vesicular stomatitis viruses and uses thereof
CN1788088B (zh) 2003-03-27 2012-09-26 渥太华健康研究学会 突变的水泡性口炎病毒及其用途
US8012747B2 (en) 2004-06-01 2011-09-06 San Diego State University Foundation Expression system
CN101065144B (zh) * 2004-08-20 2012-06-13 溶瘤病毒有限公司 治疗血液癌症的方法和组合物
US8236298B2 (en) 2004-08-20 2012-08-07 Viralytics Limited Methods and compositions for treatment of hematologic cancers
EP1917351A4 (en) 2005-08-01 2009-12-16 Univ Technologies Int ATTENUATED REOVIRUS
US10668119B2 (en) 2005-08-01 2020-06-02 Virocure, Inc. Attenuated reovirus
CA2921063C (en) 2006-09-15 2020-01-28 Ottawa Hospital Research Institute Oncolytic rhabdovirus
US10369171B2 (en) 2007-03-13 2019-08-06 Virocure, Inc. Attenuated reoviruses for selection of cell populations
AU2008340319A1 (en) * 2007-12-21 2009-07-02 Wyeth Llc Genetically modified attenuated vesicular stomatitis virus, compositions and methods of use thereof
WO2010020056A1 (en) * 2008-08-21 2010-02-25 Ottawa Hospital Research Institute Engineered synergistic oncolytic viral symbiosis
DE102008050860A1 (de) * 2008-10-08 2010-04-15 Dorothee Von Laer LCMV-GP-VSV-Pseudotypvektoren und tumorinfiltrierende Virenproduzentenzellen zur Therapie von Tumoren
ES2576036T3 (es) 2009-03-16 2016-07-05 Mcmaster University Métodos de vacunación
ES2609071T3 (es) 2009-12-10 2017-04-18 Ottawa Hospital Research Institute Rhabdovirus oncolítico
JP5944901B2 (ja) * 2010-09-02 2016-07-05 メイヨ・ファウンデーション・フォー・メディカル・エデュケーション・アンド・リサーチ 水疱性口内炎ウイルス
US9951117B2 (en) 2010-09-02 2018-04-24 Mayo Foundation For Medical Education And Research Vesicular stomatitis viruses
EP2718427B1 (en) 2011-06-08 2017-01-11 Children's Hospital of Eastern Ontario Research Institute Inc. Compositions for glioblastoma treatment
US20140335117A1 (en) 2011-10-07 2014-11-13 Skau Aps Identification and Attenuation of the Immunosuppressive Domains in Fusion Proteins of Enveloped RNA Viruses
AU2014221143B2 (en) 2013-02-21 2019-02-07 Turnstone Limited Partnership Vaccine composition
US11484567B2 (en) 2013-04-10 2022-11-01 Aarhus Universitet Use of immune suppressive domains as medicaments
WO2014198003A1 (en) 2013-06-14 2014-12-18 Ottawa Hospital Research Institute Compositions and methods for enhancing virus replication
EP2826856B9 (en) * 2013-07-16 2016-05-04 Sia Latima Genetically stable oncolytic RNA virus, method of manufacturing and use thereof
CN107076727B (zh) * 2014-07-21 2019-11-01 诺威尔卢斯德克有限公司 用于确定患者特定突变的致癌指数的方法和系统
CN105233285B (zh) * 2015-09-06 2018-10-12 广州威溶特医药科技有限公司 Epac直接或间接激动剂与溶瘤病毒的联合应用
WO2018213412A1 (en) 2017-05-19 2018-11-22 Georgia State University Research Foundation, Inc. Recombinant oncolytic virus
US10610583B2 (en) 2017-08-31 2020-04-07 Regents Of The University Of Minnesota Methods and compositions for treating glioma and medulloblastoma brain tumors using the zika virus
DK3684786T3 (da) 2017-09-22 2024-10-28 Centre Nat Rech Scient Muteret glycoprotein af vesikulær stomatitisvirus
CN110499297B (zh) * 2019-08-29 2021-07-09 上海市公共卫生临床中心 一种新型溶瘤病毒及其制备方法和应用
US20240318147A1 (en) * 2020-08-14 2024-09-26 Revoimmune Therapeutics Inc. Recombinant oncolytic virus, and construction method therefor and use thereof
EP4288140A1 (en) 2021-02-05 2023-12-13 Iovance Biotherapeutics, Inc. Adjuvant therapy for cancer
CA3212006A1 (en) 2021-02-26 2022-09-01 Kelonia Therapeutics, Inc. Lymphocyte targeted lentiviral vectors
US12440564B2 (en) 2023-09-25 2025-10-14 Kelonia Therapeutics, Inc. Compositions for treating cancer
US12269882B1 (en) 2023-09-25 2025-04-08 Kelonia Therapeutics, Inc. Antigen binding polypeptides

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1118403B (de) 1960-01-27 1961-11-30 Hoechst Ag Verfahren zur Gewinnung von antitumorwirksamen Sporen
GB1069144A (en) 1963-07-10 1967-05-17 Merck & Co Inc Method for the treatment of malignant tumors
US4806347A (en) 1985-12-11 1989-02-21 Schering Corporation Interferon combinations
ATE229344T1 (de) * 1992-03-24 2002-12-15 United Cancer Res Inst Impfstoff enthaltend lebendes virus
GB9415320D0 (en) 1994-07-29 1994-09-21 Medical Res Council Cancer treatment
US7153510B1 (en) * 1995-05-04 2006-12-26 Yale University Recombinant vesiculoviruses and their uses
WO1997026904A1 (en) 1996-01-25 1997-07-31 Medical Research Council Treatment of non-neuronal cancer using hsv mutant
PT1012244E (pt) * 1997-07-11 2007-08-21 Univ Yale ''rabdovírus com revestimentos remanipulados''
IL135507A0 (en) * 1997-10-09 2001-05-20 Pro Virus Inc Treatment of neoplasms with viruses
AP1968A (en) * 1997-12-22 2009-04-30 Univ Tennessee Res Corp Recombinant rhabdovirus containing a heterologous fusion protein.
WO1999045783A1 (en) * 1998-03-12 1999-09-16 The Trustees Of The University Of Pennsylvania Producer cells for replication selective viruses in the treatment of malignancy
ES2400445T3 (es) * 1998-06-12 2013-04-09 Mount Sinai School Of Medicine Virus atenuados con cadena de polaridad negativa con actividad antagonista de interferón alterada para uso como vacunas y productos farmacéuticos
CN1477964A (zh) * 1999-04-15 2004-02-25 应用病毒治疗肿瘤

Also Published As

Publication number Publication date
DE60041210D1 (de) 2009-02-05
EP1716858B1 (en) 2008-12-24
HK1044708A1 (en) 2002-11-01
CA2386920C (en) 2012-01-24
IL148621A0 (en) 2002-09-12
CN1496268A (zh) 2004-05-12
WO2001019380A2 (en) 2001-03-22
EP1716858A3 (en) 2007-08-15
HK1044708B (en) 2006-10-27
DE60026554T2 (de) 2006-09-28
ATE418341T1 (de) 2009-01-15
JP2004525855A (ja) 2004-08-26
IL148621A (en) 2010-02-17
AU7588200A (en) 2001-04-17
ES2320239T3 (es) 2009-05-20
NZ523805A (en) 2004-09-24
EP1218019B1 (en) 2006-03-08
HK1092713A1 (en) 2007-02-16
EP1716858B9 (en) 2009-08-12
EP1716858A2 (en) 2006-11-02
MXPA02002772A (es) 2004-04-02
JP5060694B2 (ja) 2012-10-31
ES2260057T3 (es) 2006-11-01
NZ534307A (en) 2005-07-29
NZ534306A (en) 2005-12-23
CA2386920A1 (en) 2001-03-22
AU782402B2 (en) 2005-07-28
DE60026554D1 (de) 2006-05-04
WO2001019380A3 (en) 2001-11-22
ATE319460T1 (de) 2006-03-15
NZ517573A (en) 2004-02-27
EP1218019A2 (en) 2002-07-03

Similar Documents

Publication Publication Date Title
CN1289098C (zh) 溶瘤病毒
US8147822B1 (en) Oncolytic virus
CN1820078A (zh) 弹状病毒的重组突变体及其应用方法
CN1788088A (zh) 突变的水泡性口炎病毒及其用途
CN1118569C (zh) 具有自主复制能力的负链rna病毒载体
CN1477964A (zh) 应用病毒治疗肿瘤
CN1281336A (zh) 使用病毒来治疗赘生物
CN1122105C (zh) 新的突变病毒、抗病毒化合物和新的制备疫苗的方法
CN101056646A (zh) 重组新城疫病毒
Durbin et al. PKR protection against intranasal vesicular stomatitis virus infection is mouse strain dependent
CN100346826C (zh) 通过核蛋白在磷酸化位点突变的减弱狂犬病病毒用于抗狂犬病的接种以及在cns中的基因治疗
CN1426462A (zh) 抗干扰素(ifn)反应的肺炎病毒非结构蛋白
HK1092713B (en) Oncolytic virus
HK1095608A (en) Recombinatant mutants of rhabdovirus and methods of use thereof
Gaddy Analysis of host gene products that contribute to the induction of apoptosis by oncolytic vesicular stomatitis virus
Walton Activation and Subversion of MDA5-Dependent Immune Responses by the Engineered Oncolytic Poliovirus PVSRIPO
Usai Characterization of a mouse model for the study of hepatitis delta virus infection
HK1109580A (en) Recombinant newcastle disease virus
HK1087329A (en) Dc-sign blockers and their use for preventing or treating viral infections

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20061213

Termination date: 20130918